Literature DB >> 10087113

Benign and malignant hepatocellular tumors: evaluation of tumoral enhancement after mangafodipir trisodium injection on MR imaging.

C M Coffin1, T Diche, A Mahfouz, M Alexandre, F Caseiro-Alves, A Rahmouni, N Vasile, D Mathieu.   

Abstract

The aim of this work was to study the ability of mangafodipir trisodium (Mn-DPDP)-enhanced MR imaging in differentiating malignant from benign hepatocellular tumors. Eleven patients with pathologically proved hepatocellular carcinomas, six with focal nodular hyperplasias, and one with a single hepatocellular adenoma were examined by spin-echo and gradient-echo T1-weighted sequences before, 1 h after, and 24 h after intravenous injection of Mn-DPDP (5 micromol/kg). Quantitative analysis including enhancement and lesion-to-liver contrast-to-noise ratio, and qualitative analysis including the presence of a central area and a capsule were done on pre- and post-Mn-DPDP-enhanced images. Enhancement was observed in all the tumors with significant improvement (p < 0.05) in contrast-to-noise ratio 1 h after, and 24 h after intravenous injection of Mn-DPDP. There were no significant differences in the mean enhancement and the mean contrast-to-noise ratio (CNR) between benign and malignant tumors. No enhancement was seen within internal areas observed in 7 hepatocellular carcinomas, and in 5 focal nodular hyperplasias, and within capsules which were observed in 9 hepatocellular carcinomas. In our study, Mn-DPDP increased CNR of both benign and malignant tumors but did not enable differentiation between benign and malignant tumors of hepatocellular nature.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10087113     DOI: 10.1007/s003300050689

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  8 in total

1.  Mn-DPDP-enhanced 24-h delayed-scan MRI of hepatocellular carcinoma is correlated with histology.

Authors:  Deng-Bin Wang; Kang-Rong Zhou; Meng-Su Zeng; Ke-Min Chen; Yi-Xiang J Wang
Journal:  Eur Radiol       Date:  2003-06-12       Impact factor: 5.315

Review 2.  [Diagnosis and differential diagnosis of benign liver tumors and tumor-like lesions].

Authors:  M Galanski; S Jördens; J Weidemann
Journal:  Chirurg       Date:  2008-08       Impact factor: 0.955

3.  Detection of colorectal liver metastases: a prospective multicenter trial comparing unenhanced MRI, MnDPDP-enhanced MRI, and spiral CT.

Authors:  Carlo Bartolozzi; Francescamaria Donati; Dania Cioni; Carlo Procacci; Giovanni Morana; Antonio Chiesa; Luigi Grazioli; Giorgio Cittadini; Giuseppe Cittadini; Andrea Giovagnoni; Giovanni Gandini; Jochen Maass; Riccardo Lencioni
Journal:  Eur Radiol       Date:  2003-08-09       Impact factor: 5.315

Review 4.  Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications.

Authors:  Peter Reimer; Günter Schneider; Wolfgang Schima
Journal:  Eur Radiol       Date:  2004-02-25       Impact factor: 5.315

Review 5.  Biliary and reticuloendothelial impairment in hepatocarcinogenesis: the diagnostic role of tissue-specific MR contrast media.

Authors:  Carlo Bartolozzi; Laura Crocetti; Riccardo Lencioni; Dania Cioni; Clotilde Della Pina; Daniela Campani
Journal:  Eur Radiol       Date:  2007-02-16       Impact factor: 7.034

6.  Quantifying liver cirrhosis by extracting significant features from MRI T2 image.

Authors:  Ming-Hong Hshiao; Po-Chou Chen; Jo-Chi Jao; Yung-Hui Huang; Chen-Chang Lee; Shih-Yu Chao; Li-Wei Lin; Tai-Been Chen
Journal:  ScientificWorldJournal       Date:  2012-06-18

Review 7.  Contrast agents for hepatic MRI.

Authors:  Giovanni Morana; Elisabetta Salviato; Alessandro Guarise
Journal:  Cancer Imaging       Date:  2007-10-01       Impact factor: 3.909

Review 8.  Distinguishing benign from malignant liver tumours.

Authors:  Jay P Heiken
Journal:  Cancer Imaging       Date:  2007-10-01       Impact factor: 3.909

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.